Secretoneurin as a novel predictor of metabolic syndrome in patients with obstructive sleep apnea syndrome.

İbrahim Arslan, Yasin Aslan, Muzaffer Arı, Hamit Yaşar Ellidağ, Ömer Tarık Selçuk

Abstract read

In one paragraph

Article in Brazilian journal of otorhinolaryngology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

İbrahim ArslanAntalya Education and Research Hospital, Department of Ear, Nose, and Throat, Antalya, Turkey. Electronic address: dr.arslanibrahim@gmail.com.

Yasin AslanAntalya Education and Research Hospital, Department of Ear, Nose, and Throat, Antalya, Turkey.

Muzaffer ArıAntalya Education and Research Hospital, Department of Ear, Nose, and Throat, Antalya, Turkey.

Hamit Yaşar EllidağAntalya Education and Research Hospital, Department of Medical Biochemistry, Antalya, Turkey.

Ömer Tarık SelçukAntalya Education and Research Hospital, Department of Ear, Nose, and Throat, Antalya, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to evaluate whether Secretoneurin (SN) was elevated in Metabolic Syndrome (MetS) and could serve as a potential predictive biomarker in the development of MetS in patients with Obstructive Sleep Apnea Syndrome (OSAS).

methodsThis cross-sectional study included 86 consecutive participants. Following anthropometric measurements, blood tests, polysomnography, and blood pressure assessments, the participants were categorized into three groups: the MetS(+) OSAS group, the MetS(-) OSAS group, and the control group without MetS or OSAS. Serum SN levels were measured using the enzyme-linked immunosorbent assay method.

resultsThe SN levels (pmol/L) of the MetS(+) OSAS group were statistically higher than those of the MetS(-) OSAS group and the control group (p < 0.033). A positive and statistically significant correlation was observed between SN levels (pmoL/L) and serum triglyceride levels (mg/dL) (r = 0.244, p = 0.024 < 0.05).

conclusionsThis study indicates that SN may have predictive value in the development of MetS in patients with OSAS. LEVEL OF EVIDENCE: 4:

Indexed as

Metabolic SyndromeNeuropeptidesSecretogranin IISleep Apnea, ObstructiveAdultBiomarkersCase-Control StudiesCross-Sectional StudiesEnzyme-Linked Immunosorbent AssayFemaleHumansMaleMiddle AgedPolysomnographyPredictive Value of TestsTriglyceridesBiomarkersNeuropeptidesSecretogranin IIsecretoneurinTriglyceridesCardiovascular diseaseHypoxiaMetabolic syndromeObstructive sleep apneaSecretoneurin

Identifiers

PMID42302465

DOI10.1016/j.bjorl.2026.101856

PMCPMC13285276

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.